ClinicalTrials.gg
CompletedNCT00786994Updated Sep 14, 2015Results posted

The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses

A Phase 2 interventional study of Oleogel-S10 100 mg/g and Placebo (petroleum jelly) in Actinic Keratoses, sponsored by Birken AG. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-14.

Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Keratosis, Actinic with a site in Germany — 4 open to participants now, 6 under way, 1 of them phase 3. Keratosis, Actinic · Germany.

Enrollment
20th of 45
165 · median 137
Started
2008
with 3 others
Phase 2
11 of 53
none open now
Registered
9th of 53
by date

Among the 53 studies in Keratosis, Actinic with a site in Germany, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2008, is one of 11 in phase 2, and was the 9th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

4 of the 53 studies in Keratosis, Actinic with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Keratosis, Actinic with a site in Germany, or all of them as a file.
02

Study summary

In this study the impact of Oleogel-S-10 versus placebo on actinic keratoses over a treatment period of 3 months will be tested. Additionally, once and twice daily applications are tested.

Read the detailed description

Oleogel-S-10 has shown efficacy and was well tolerated in two previous clinical trials. In the second open label phase II trial the efficacy of Oleogel-S-10 alone was similar compared to a more invasive treatment with cryotherapy. Response rates of 85% with a clear-ance of more than 75 % of the lesions of the patients treated with Oleogel-S-10 over three months were reported. These encouraging results led to the present randomized, multicenter, double blind phase II trial. The efficacy of the treatment shall be tested in a double blind placebo controlled (petroleum jelly) fashion in order to obtain more reliable results for the planning of a phase III study.

03

Conditions studied

  • Actinic Keratoses

Browse trials for

Keywords

  • Actinic Keratoses
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least two mild to moderate actinic keratoses located at the facial skin or the head (except lips)
  • Actinic keratoses with a diameter of 0,5 - 2 cm,

    • that are definitely distinguished from other lesions and display a minimum distance of 0,5 cm to neighbored lesions
    • that are evaluated as histopathological grade 1 to 3
  • proven AK within three months before study entry
  • prepared and able to give written
  • ≥ 18 years of age
  • In case of females: defined as

    • natural menopause with menses > 1 year ago
    • serum FSH (> 20 IU/l) and E2 levels in the postmenopausal range or
    • patients who had bilateral oophorectomy
  • prepared and comply with all study requirements, including the following:

    • application of Oleogel-S10 on the treatment area once or twice a day
    • 4 clinic visits during the pre-study, treatment, post-treatment, and follow-up period
    • pre- and post-treatment for histological confirmation (of clearance) of AK-diagnosis
  • Representative histologic slide and tissue block were shipped

Exclusion criteria

Exclusion Criteria:

  • Active therapy
  • data of , unstable, cardiovascular or hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or diseases Note: Patients with clinically stable medical conditions including, but not limited to, controlled hypertension, diabetes mellitus type II, hypercholesterolemia, or osteoarthritis will be allowed to enter the study
  • known allergies to any in the study drug
  • any dermatological disease and/or condition in the treatment or surrounding area (3 cm distances from treatment area) that may be exacerbated by treatment with Oleogel-S-10 or cause difficulty with examination
  • active chemical dependency or alcoholism, as assessed by the investigator
  • pregnant and lactating women
  • currently participating in another clinical study or have completed another clinical study with an drug within the past 30 days
  • received topical treatment at the treatment area with diclofenac gel, imiquimod or 5-FU within a time period of 1 month
  • Concomitant existence of non-treated (non-excised) basal cell carcinoma, squamous cell carcinoma or malignant melanoma
  • Invasive tumors within the treatment area, e.g.: merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma, the latter is accepted if completely surgically removed Note: A of any lesion within the treatment or surrounding area suggestive of should be performed at the pre-study screening visit. If invasive SCC or other malignant conditions are confirmed within the treatment area, the patient will not be included in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    1

    Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)

    Drug: Oleogel-S10 100 mg/g

  • Experimental
    2

    Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)

    Drug: Oleogel-S10 100 mg/g

  • Placebo comparator
    3

    Placebo (petroleum jelly) for three months once a day (27 patients)

    Drug: Placebo (petroleum jelly)

  • Placebo comparator
    4

    Placebo (petroleum jelly) for three months twice a day (27 patients)

    Drug: Placebo (petroleum jelly)

Interventions

  • DrugOleogel-S10 100 mg/g

    Drug pages: Episalvan · Birch triterpenes

    topical use once or twice daily

  • DrugPlacebo (petroleum jelly)

    topical use once or twice daily

    Also known as: Vaseline

06

What researchers measure

Primary outcomes

  1. Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance.

    Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy. The Cockerell classification refers to a single lesion, graded as the presence of atypical cells in the lower third of the epidermis (grade I), involvement of at least the lower two-thirds (grade II) or atypical keratinocytic proliferation in the entire epidermis (grade III). Thus a down-grading from a higher Cockerell grade (e.g., III) to a lower Cockerell grade (e.g., I) represents a positive outcome and treatment success.

    Time frame: 18 weeks

07

Results

Posted Aug 14, 2015

Participant flow

165 patients were recruited.

Participant flow — Overall Study
MilestoneA - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice Daily
Started57542628
Itt53512528
Completed47392422
Not completed101526

Outcome measures

PrimaryObjective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance.

Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy. The Cockerell classification refers to a single lesion, graded as the presence of atypical cells in the lower third of the epidermis (grade I), involvement of at least the lower two-thirds (grade II) or atypical keratinocytic proliferation in the entire epidermis (grade III). Thus a down-grading from a higher Cockerell grade (e.g., III) to a lower Cockerell grade (e.g., I) represents a positive outcome and treatment success.

Time frame:
18 weeks
Reported as:
Number · participants
Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance.
participantsA - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC/D - Placebo Once or Twice Daily
Success: Downgrading or clearance221719
Failure: No downgrading or clearance252227
Statistical analysis
  • A - Oleogel-S10 Once Daily vs C/D - Placebo Once or Twice Daily · Mantel Haenszel · p = 0.60
  • B - Oleogel-S10 Twice Daily vs C/D - Placebo Once or Twice Daily · Mantel Haenszel · p = 0.83

Adverse events

Collected over Treatment period of 18 weeks: Visits at 0, 6, 12 and 18 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A - Oleogel-S10 Once Daily—2/57 (3.5%)3/57 (5.3%)
B - Oleogel-S10 Twice Daily—3/54 (5.6%)7/54 (13%)
C - Placebo Once Daily—0/26 (0%)3/26 (11.5%)
D - Placebo Twice Daily—0/28 (0%)3/28 (10.7%)
Most frequent serious events
Most frequent serious events
EventA - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice Daily
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/571/540/260/28
Prolaps of intervertebral discMusculoskeletal and connective tissue disorders0/571/540/260/28
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/571/540/260/28
Fracture of ribInjury, poisoning and procedural complications1/570/540/260/28
Respiratory infectionInfections and infestations1/570/540/260/28
Most frequent other events
Most frequent other events
EventA - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice Daily
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/571/540/262/28
RashSkin and subcutaneous tissue disorders0/573/541/260/28
PruritusSkin and subcutaneous tissue disorders0/571/541/260/28
Allergic reaction/hypersensitivity (including drug fever)Immune system disorders0/570/541/260/28
Flu-like syndromeInfections and infestations0/572/540/261/28
Gastritis (including bile reflux gastritis)Gastrointestinal disorders2/570/540/260/28
Cough / upper respiratory tract infectionInfections and infestations2/570/540/260/28

Baseline characteristics

ITT

Age, Continuous
Age, Continuous(years)A - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice DailyTotal
Median72 (61 to 88)74 (56 to 85)69 (57 to 81)72 (51 to 83)72 (51 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)A - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice DailyTotal
Female41422025128
Male1295329
Actinic keratosis baseline severity index
Actinic keratosis baseline severity index(participants)A - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice DailyTotal
Mild221891362
Moderate3133161595
Histopathological grading
Histopathological grading(participants)A - Oleogel-S10 Once DailyB - Oleogel-S10 Twice DailyC - Placebo Once DailyD - Placebo Twice DailyTotal
Grade I942217
Grade II111041237
Grade III32361913100
not done11013
08

Study locations

6 sites
  • Charité University Hospital
    Berlin, Germany
  • University Dermatology Hospital
    Freiburg, Germany
  • University Dermatology Hospital
    Tübingen, Germany
  • Dermatology practice
    Wuppertal, Germany
  • National University, "Andreas Syggros" Skin & Venereal Diseases Hospital
    Athens, Greece
  • University Dermatology Hospital
    Heraklion, Greece
09

References and documents

Publications

  • Pflugfelder A, Andonov E, Weide B, Dirschka T, Schempp C, Stockfleth E, Stratigos A, Kruger-Krasagakis S, Bauer J, Garbe C, Eigentler TK. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. Br J Dermatol. 2015 Apr;172(4):926-32. doi: 10.1111/bjd.13342. Epub 2015 Feb 25. PubMed 25124939 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2008
First posted
Nov 6, 2008
Start
Oct 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Aug 14, 2015
Last update
Sep 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00786994
Lead sponsor
Birken AG
Responsible party
Sponsor
First posted
Nov 6, 2008
Start date
Oct 2008
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Aug 14, 2015
Last update
Sep 14, 2015

Study contacts

Claus Garbe, Prof. Dr.
principal investigator · Universitätshautklinik Tübingen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Episalvan · Birch triterpenes

Start the discussion